Shares of Fresenius SE & Co KGaA (FRA:FRE) have been assigned a consensus recommendation of “Buy” from the sixteen brokerages that are covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is €55.37 ($64.38).
A number of equities research analysts recently issued reports on FRE shares. DZ Bank reissued a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Monday, November 4th. HSBC set a €53.00 ($61.63) target price on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Thursday, November 21st. Goldman Sachs Group set a €53.00 ($61.63) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Tuesday, November 5th. Sanford C. Bernstein set a €52.00 ($60.47) price target on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Tuesday, November 12th. Finally, Deutsche Bank set a €65.00 ($75.58) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Wednesday, October 30th.
Shares of FRE traded up €0.41 ($0.48) during midday trading on Friday, reaching €48.45 ($56.34). The company had a trading volume of 1,564,889 shares. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($69.95) and a 1-year high of €80.00 ($93.02). The firm has a 50 day simple moving average of €49.78 and a 200-day simple moving average of €46.34.
About Fresenius SE & Co KGaA
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.